Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 5 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

0
Player Avatar whitc08202 (22.45) Submitted: 8/17/2012 10:44:30 AM : Outperform Start Price: $4.34 EXEL Score: -7.30

Under priced stock.

Featured Broker Partners


Advertisement